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One of the greatest clinical needs in cancer diagnostics is
the accurate detection of early-stage tumors that have not
yet metastasized. Treatment of such early lesions is
expected to have a direct impact on long-term survival. In
contrast, once dissemination and organ colonization has
begun, the effectiveness of all conventional therapy is
limited. By definition, such early-stage lesions are very
small (less than 0.5 cm) and often exist below the threshold
of detection by sophisticated imaging such as MRI. Brown
and Palmer [1] have estimated that a test for ovarian cancer
would have to detect tumors smaller than 0.5 cm to achieve
a 50% reduction in cancer mortality with an annual screen.
Putative biomarkers elaborated into the circulation from a
small pre-metastatic lesion will be diluted in the entire
blood volume and can be subject to rapid clearance by a
variety of mechanisms [2]. Thus, the expected concentra-
tion of a blood-borne diagnostic analyte derived from these
crucially important, but tiny, clinical lesions will be much
less than 1 ng/ml and will likely fall in the picograms-per-
milliliter range [1, 2].
Despite the rapid advancements in the application of mass
spectrometry (MS) to biomarker discovery and quantitative
measurement [3], serious physiologic challenges still
remain that limit the sensitivity of MS. Consequently, the
analytical sensitivity of MS for biomarker discovery is
actually very low, particularly when applied to complex
protein mixtures such as blood. Cancer-associated blood
biomarkers exist within a sea of high-abundance proteins
such as albumin and immunoglobulins. Moreover, circulat-
ing biomarkers are subjected to degradation during
transportation and storage, further reducing their concen-
tration. In part because of these physiologic limitations, the
vast majority of hundreds of clinical analytes measured
routinely in the clinical chemistry laboratory today cannot
be detected by current MS discovery approaches [4]. MS is
simply not sensitive enough to detect the typical clinical
analyte that falls in the range of 50 pg/ml to 5 ng/ml.
Established clinical immunoassays stand as tough compe-
tition because they are highly precise, reliable, and low in
cost. In its current form, the routine sensitivity threshold
MRM technology [3] is tens of nanograms per milliliter.
The sensitivity of MRM needs to be improved 100-fold in
order to compete with clinical immunoassays. This is a
sobering reality for proponents of MS who hope it will
replace conventional immunoassays.
The majority of proteins cataloged by MS under the
HUPO human plasma proteome project falls in the high-
abundance range [4]. Thus, a biomarker considered by MS
to be negative in a sample may actually be present in the
sample at a concentration below the level of MS sensitivity.
A more sensitive technology such as protein array or
ELISA may therefore detect a candidate biomarker in a
control sample considered to be negative by MS. This
should not be considered a false positive.
Fortunately, advances in nanotechnology, and affinity
capture concentration, are providing a completely new
approach to increase the sensitivity of MS for biomarker
discovery [5–7]. Biomarker “harvesting” nanoparticles
rapidly concentrate low abundance proteins for MS, MRM,
or immunoassay-based analysis. The nanoparticles are com-
prised of a shell with defined porosity surrounding a core
containing an affinity bait. Harvesting nanoparticle technol-
ogy [5, 6] has been documented to increase the sensitivity of
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mass spectrometry and clinical immunoassay detection by
more than 100-fold, with high precision, without increasing
the background signal [6]. The added benefit of harvesting
nanoparticles is their ability to completely protect the
captured analyte from degradation [5, 6].
Affinity capture nanoparticles increase the sensitivity of
MS by concentrating all the analyte molecules in a large
sample volume into a very small volume for introduction
into the MS. Nanoparticles also exclude the vast excess of
high-abundance proteins, such as albumin, in the original
biologic fluid by performing size exclusion. An alternative
approach to analyte concentration and pre-separation is
antibody affinity capture [7]. In this technology, immobi-
lized antibodies, even those of low specificity for the target
analyte, are employed to capture and concentrate the
analyte prior to introduction into the MS. Recently, the
sensitivity of immuno-MS has reached the 0.5 ng/ml range
when applied to cardiovascular markers [7]. The success of
these two different classes of affinity enrichment
technologies provides optimism that the sensitivity and
pre-analytical variability of MS can be substantially
improved. Unfortunately, MS, even with technical enhance-
ments, cannot currently compete with clinical immuno-
assays on cost, sensitivity, or precision. Instead, MS should
play to its strengths: the high accuracy identification of
disease-related posttranslational modifications, specific
fragments, and protein isoforms. Modified forms of protein
are not easily detected by conventional immunoassays.
Consequently, for this class of modified analytes, MS
would not have much competition.
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